Supplemental Data from Loss of Estrogen-Regulated MIR135A1 at 3p21.1 Promotes Tamoxifen Resistance in Breast Cancer

Weijie Zhang,Mingming Wu,Qing-Yun Chong,Min Zhang,Xiao Zhang,Lan Hu,Yanghao Zhong,Pengxu Qian,Xiangjun Kong,Sheng Tan,Gaopeng Li,Keshuo Ding,Peter E. Lobie,Tao Zhu

DOI: https://doi.org/10.1158/0008-5472.22425688.v1

2023-01-01

Abstract:Supplementary table S1 lists all the sequence of miR-135a mimic, siRNAs, shRNAs, and primers for plasmid construction, ChIP assay, and qRT-PCR used in this study. Supplementary table S2 shows the information of antibodies used in this study. Supplementary table S3 and S4 show the correlation of MIR135A1 deletion and low miR-135a-1 with the clinicopathologic features of breast cancer in the TCGA breast tumors, respectively. Supplementary table S5 lists genes including EMT markers, ERα cofactors and interacting proteins, and predicted miR-135a targets which expression levels negatively correlate with miR-135a in breast tumors. Supplementary figure S1 shows that the copy number of MIR135A1 gene and the expression levels of pri-miR-135a-1 are decreased in breast cancer. Supplementary figure S2 shows that miR-135a is a tumor suppressor gene in T47D and MDA-MB-231 cells and inhibits EMT of breast cancer cells. Supplementary figure S3 shows that miR-135a impairs the in vivo tumor growth. Supplementary figure S4 shows that the transcription of MIR135A1 positively correlates with E2-ERα axis. Supplementary figure S5 shows that miR-135a modulates the estrogen independent growth and the response to tamoxifen in ERα+ breast cancer cells. Supplementary figure S6 shows the validation of miR-135a targets in breast cancer cells. Supplementary figure S7 shows that miR-135a modulates ERα-ERK-AKT crosstalk.